Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + lenalidomide + rituximab + ifosfamide + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ZR2-ICE is a multi-drug combination immunochemotherapy regimen being investigated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The regimen consists of the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib, the immunomodulatory agent lenalidomide, and the R-ICE chemotherapy backbone (rituximab, ifosfamide, carboplatin, and etoposide). This combination aims to enhance the efficacy of salvage therapy by targeting multiple pathways, including B-cell receptor signaling, immune modulation, and cytotoxic DNA damage. It is currently being evaluated in a Phase 2 clinical trial sponsored by RenJi Hospital.
- Other names
- ZR2-ICEZR-2-ICEZR 2-ICE
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)CRBN (Cereblon)DNABTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on zanubrutinib + lenalidomide + rituximab + ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + lenalidomide + rituximab + ifosfamide + carboplatin + etoposide.